--- title: "Eli Lilly's application for a new indication of Tirzepatide injection has been accepted in China" type: "News" locale: "en" url: "https://longbridge.com/en/news/265654691.md" description: "On November 13th, the CDE official website showed that Eli Lilly's glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor dual agonist tirzepatide injection's new indication application has been accepted. This is the third indication approval for the drug in China after its initial approval. In May 2024, tirzepatide was first approved for marketing in China for adult patients with type 2 diabetes (T2DM) whose blood sugar is still poorly controlled despite diet control and treatment with metformin and/or sulfonylureas. In July 2024, tirzepatide was approved for a new indication in China: for long-term weight management in adults with a body mass index (BMI) meeting the following criteria based on diet control and increased physical activity: ≥28 kg/m2 (obesity) or ≥24 kg/m2 (overweight) with at least one weight-related comorbidity (such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, cardiovascular disease, etc.). In June of this year, tirzepatide was approved for a third indication in China: for the treatment of moderate to severe obstructive sleep apnea (OSA) in adult patients with obesity" datetime: "2025-11-13T07:05:02.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/265654691.md) - [en](https://longbridge.com/en/news/265654691.md) - [zh-HK](https://longbridge.com/zh-HK/news/265654691.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/265654691.md) | [繁體中文](https://longbridge.com/zh-HK/news/265654691.md) # Eli Lilly's application for a new indication of Tirzepatide injection has been accepted in China According to Zhitong Finance APP, on November 13, the CDE official website showed that Eli Lilly (LLY.US) has received acceptance for the new indication application for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor dual agonist tirzepatide injection. This is the third indication approval for this drug in China. ![Image](https://imageproxy.pbkrs.com/http://img.zhitongcaijing.com/images/contentformat/7137aef9676ef9122114e6c258d2b197.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg) In May 2024, tirzepatide was first approved for marketing in China for adult patients with type 2 diabetes (T2DM) whose blood sugar is still poorly controlled despite treatment with metformin and/or sulfonylureas, based on dietary control and exercise. In July 2024, tirzepatide was approved in China for a new indication: for long-term weight management in adults with a body mass index (BMI) meeting the following criteria: ≥28 kg/m2 (obesity), or ≥24 kg/m2 (overweight) with at least one weight-related comorbidity (such as hypertension, dyslipidemia, hyperglycemia, obstructive sleep apnea, cardiovascular diseases, etc.), based on dietary control and increased physical activity. In June of this year, tirzepatide was approved in China for a third indication: for the treatment of moderate to severe obstructive sleep apnea (OSA) in adult patients with obesity ### Related Stocks - [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md) ## Related News & Research - [Eli Lilly pushes for NHS drug price increases in return for its UK investment, FT reports](https://longbridge.com/en/news/280952509.md) - [Lilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disorders | LLY Stock News](https://longbridge.com/en/news/281171668.md) - [InSilico Medicine's Loss Widens in 2025; Enters Licensing Agreement With Eli Lilly](https://longbridge.com/en/news/280951810.md) - [](https://longbridge.com/en/news/281203519.md) - [Lilly To Acquire Centessa; Upfront Consideration Represents Equity Value Of Approx. $6.3 Bln](https://longbridge.com/en/news/281174134.md)